Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Biomarkers in Primary Progressive Multiple Sclerosis and Hereditary Spastic Paraplegia Type 4

Blood GFAP as an emerging biomarker in brain and spinal cord disorders

(2022) Ahmed Abdelhak et al.   Nature Reviews Neurology

Characteristics of serum neurofilament light chain as a biomarker in hereditary spastic paraplegia type 4

(2022) Christoph Kessler et al.   Annals of Clinical and Translational Neurology

Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study

(2022) Pascal Benkert et al.   LANCET NEUROLOGY

Neurofilament light chain is a cerebrospinal fluid biomarker in hereditary spastic paraplegia

(2021) Christoph Kessler et al.   Annals of Clinical and Translational Neurology

A lymphocyte–microglia–astrocyte axis in chronic active multiple sclerosis

(2021) Martina Absinta et al.   NATURE

NfL and pNfH are increased in Friedreich’s ataxia

(2020) Stefanie Nicole Hayer et al.   JOURNAL OF NEUROLOGY

Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice

(2020) Carlo Wilke et al.   EMBO Molecular Medicine

Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity

(2020) Xavier Ayrignac et al.   Scientific Reports

Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis

(2019) Hans Lassmann   Frontiers in Immunology

Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?

(2019) Ahmed Abdelhak et al.   Frontiers in Neurology

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response

(2019) Jens Kuhle et al.   NEUROLOGY

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis

(2019) Benjamin Turner et al.   JOURNAL OF NEUROLOGY

Neurofilament light chain as a biomarker in neurological disorders

(2019) Lorenzo Gaetani et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis

(2018) Christian Barro et al.   BRAIN

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

(2018) Alan J Thompson et al.   LANCET NEUROLOGY

Serum neurofilament light chain is increased in hereditary spastic paraplegias

(2018) Carlo Wilke et al.   Annals of Clinical and Translational Neurology

Astrocytes play a crucial role in the formation and evolution of MS lesions – Yes

(2018) David Pitt et al.   Multiple Sclerosis Journal

Serum GFAP as a biomarker for disease severity in multiple sclerosis

(2018) A. Abdelhak et al.   Scientific Reports

Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity

(2018) Heidi Högel et al.   Multiple Sclerosis Journal

CSF Neurofilament Light Chain Levels in Primary Progressive MS: Signs of Axonal Neurodegeneration

(2018) Marc Pawlitzki et al.   Frontiers in Neurology

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

CSF profile in primary progressive multiple sclerosis: Re-exploring the basics

(2017) Ahmed Abdelhak et al.   PLoS One

Hereditary spastic paraplegia: Clinicogenetic lessons from 608 patients

(2016) Rebecca Schüle et al.   ANNALS OF NEUROLOGY

Gene dosage-dependent rescue of HSP neurite defects in SPG4 patients' neurons

(2014) S. Havlicek et al.   HUMAN MOLECULAR GENETICS

Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation

(2014) Lior Mayo et al.   NATURE MEDICINE

Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis

(2010) M. Axelsson et al.   JOURNAL OF NEUROLOGY

The relation between inflammation and neurodegeneration in multiple sclerosis brains

(2009) Josa M. Frischer et al.   BRAIN